Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Brukinsa showed superior PFS and ORR compared to Rituxan in CLL/SLL patients, with a 71% risk reduction in progression or death. Brukinsa's efficacy was consistent across various risk factors, ...

Treatment for colorectal cancer varies based on the cancer’s stage, how well it responds to therapy, and the person’s overall health, with newer treatments offering improved outcomes. Common ...

EU Committee recommends approval of AstraZeneca’s camizestrant for 1st-line advanced ER-positive breast cancer: Cambridge, UK Monday, May 25, 2026, 09:00 Hrs [IST] AstraZenecas ...

Radiofrequency treatment is normally used to tighten the skin around the eyes for aesthetic purposes. It’s generally safe, minimally invasive, and suitable for all skin colors. The technique is now ...

Panelists discuss how quadruplet regimens show improved efficacy over triplet regimens without significantly increased safety concerns, with anti-CD38 antibodies being well tolerated and NCCN ...

Panelists discuss how the current treatment landscape for patients with late-line relapsed/refractory multiple myeloma (RRMM) involves novel approaches such as bispecific antibodies, CAR-T cell ...

Before the discovery of newer options and combinations, chemotherapy that included platinum medications like cisplatin or carboplatin was the first choice, says Christopher Wee, MD, a genitourinary ...

Numerous advances in the standard of care for metastatic colorectal cancer (mCRC), including the approval of several new treatments indicated for treatment in the third line or later (3L+), have been ...

From September 2016 through June 2018, a total of 707 children and adolescents who weighed at least 14 kg were randomly assigned to receive dolutegravir-based ART (350 participants) or standard care ...